PUM1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: PUM1

NCBI ID: G9698

PUM1

PUM1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Pumilio RNA binding family member 1 (PUM1) is a protein that plays an essential role in the regulation of gene expression in various organisms, including humans. PUM1 is a member of the Pumilio RNA binding family, which is known for its ability to interact with RNA molecules and regulate gene expression. PUM1 has been identified as a potential drug target and has been shown to be involved in a variety of biological processes, including cancer, neurodegenerative diseases, and autoimmune disorders.

PUM1 and its Functions

PUM1 is a protein that was identified as a potential drug target due to its ability to interact with several different RNA molecules. PUM1 has been shown to interact with microRNA (miRNA), double-stranded RNA (dsRNA), and RNA-protein interactions. These interactions allow PUM1 to regulate gene expression and contribute to the function of the Pumilio RNA binding family.

One of the key functions of PUM1 is its ability to interact with miRNA. PUM1 has been shown to physically interact with miRNA through a process called base pairing, which allows PUM1 to base pair with specific locations on the miRNA molecule. This interaction between PUM1 and miRNA can lead to the regulation of gene expression, including the translation of certain genes into protein.

Another function of PUM1 is its ability to interact with dsRNA. PUM1 has been shown to form a complex with dsRNA, which can lead to the formation of RNA-protein complexes. These complexes can then act as targets for various enzymes, including RNA-protein hybrids and RNA-protein interactions.

PUM1 and Cancer

PUM1 has been shown to be involved in the regulation of gene expression in cancer cells. Several studies have shown that PUM1 is involved in the regulation of cancer cell growth, apoptosis, and angiogenesis. For example, one study found that PUM1 was involved in the regulation of the expression of the tumor suppressor gene, TP53, in human breast cancer cells.

In addition, PUM1 has also been shown to contribute to the development and progression of certain types of cancer. For example, one study found that PUM1 was involved in the regulation of the expression of genes that are associated with cancer cell survival and angiogenesis in colon cancer cells.

PUM1 and Neurodegenerative Diseases

PUM1 has also been shown to be involved in the regulation of gene expression in neurodegenerative diseases. For example, one study found that PUM1 was involved in the regulation of the expression of genes that are associated with neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition, PUM1 has also been shown to contribute to the development and progression of certain types of neurodegenerative diseases. For example, one study found that PUM1 was involved in the regulation of the expression of genes that are associated with the development of neurodegenerative diseases, including dystopian diseases.

PUM1 and Autoimmune Disorders

PUM1 has also been shown to be involved in the regulation of gene expression in autoimmune disorders. For example, one study found that PUM1 was involved in the regulation of the expression of genes that are associated with autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

In addition, PUM1 has also been shown to contribute to the development and progression of certain types of autoimmune disorders. For example, one study found that PUM1 was involved in the regulation of the expression of genes that are associated with the development of autoimmune disorders, including Crohn's disease.

PUM1 as a Drug Target

The potential drug targets for PUM1 include targets that

Protein Name: Pumilio RNA Binding Family Member 1

Functions: Sequence-specific RNA-binding protein that acts as a post-transcriptional repressor by binding the 3'-UTR of mRNA targets. Binds to an RNA consensus sequence, the Pumilio Response Element (PRE), 5'-UGUANAUA-3', that is related to the Nanos Response Element (NRE) (PubMed:21572425, PubMed:18328718, PubMed:21653694, PubMed:21397187). Mediates post-transcriptional repression of transcripts via different mechanisms: acts via direct recruitment of the CCR4-POP2-NOT deadenylase leading to translational inhibition and mRNA degradation (PubMed:22955276). Also mediates deadenylation-independent repression by promoting accessibility of miRNAs (PubMed:18776931, PubMed:20818387, PubMed:20860814, PubMed:22345517). Following growth factor stimulation, phosphorylated and binds to the 3'-UTR of CDKN1B/p27 mRNA, inducing a local conformational change that exposes miRNA-binding sites, promoting association of miR-221 and miR-222, efficient suppression of CDKN1B/p27 expression, and rapid entry to the cell cycle (PubMed:20818387). Acts as a post-transcriptional repressor of E2F3 mRNAs by binding to its 3'-UTR and facilitating miRNA regulation (PubMed:22345517, PubMed:29474920). Represses a program of genes necessary to maintain genomic stability such as key mitotic, DNA repair and DNA replication factors. Its ability to repress those target mRNAs is regulated by the lncRNA NORAD (non-coding RNA activated by DNA damage) which, due to its high abundance and multitude of PUMILIO binding sites, is able to sequester a significant fraction of PUM1 and PUM2 in the cytoplasm (PubMed:26724866). Involved in neuronal functions by regulating ATXN1 mRNA levels: acts by binding to the 3'-UTR of ATXN1 transcripts, leading to their down-regulation independently of the miRNA machinery (PubMed:25768905, PubMed:29474920). Plays a role in cytoplasmic sensing of viral infection (PubMed:25340845). In testis, acts as a post-transcriptional regulator of spermatogenesis by binding to the 3'-UTR of mRNAs coding for regulators of p53/TP53. Involved in embryonic stem cell renewal by facilitating the exit from the ground state: acts by targeting mRNAs coding for naive pluripotency transcription factors and accelerates their down-regulation at the onset of differentiation (By similarity). Binds specifically to miRNA MIR199A precursor, with PUM2, regulates miRNA MIR199A expression at a postranscriptional level (PubMed:28431233)

The "PUM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PUM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets